Abdurrahman Tufan: Combination Targeted Therapy in Refractory Systemic Autoinflammatory Diseases
Abdurrahman Tufan, Clinical Consultant and Instructor at Gazi University, shared a post on LinkedIn:
“I’m very pleased to share our new publication in Seminars in Arthritis and Rheumatism:
‘Biologic biologic and biologic JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases.’
Our findings demonstrate the potential of combination targeted therapy to achieve sustained disease control in selected patients with severe and refractory systemic autoinflammatory diseases (SAIDs), including those with persistent inflammation and limited therapeutic options.
In this retrospective longitudinal cohort from the NIH Inflammatory Disease Section, we evaluated advanced combination therapy (ACT) using biologics and or JAK inhibitors in patients with difficult to treat SAIDs.
Among 38 patients, 65 ACT regimens were administered. Following multiple treatment trials:
- 55.3 percent achieved a complete response
- 31.6 percent achieved a partial response
- 68 percent of patients remained on combination therapy at final follow up
- Median duration of ACT was 5 years (range 11 to 186 months)
I am very grateful to all of my co authors and colleagues who contributed to this study, and especially to Daniel L. Kastner, whose mentorship and vision have profoundly influenced our work in autoinflammatory diseases.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke